REFERENCE FILE
Tesamorelin
Examine the reference details alongside the questions and dated sources.
Reference details
Status as of
- Regulatory category
- Approved product
- Evidence category
- Randomized evidence
- Mechanism
- Stimulates growth-hormone release.
- Evidence
- A randomized trial measured visceral fat.
- Limitations
- Not for weight management.
- Safety
- Active malignancy is a contraindication.
- Formulation and route
- Specified subcutaneous formulation.
- Approval scope
- Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.
READING NOTES
Questions for a closer look
Inspect a percentage in a tesamorelin discussion by asking what one counted item would look like. Would an entry represent a person, an episode, a visit or something else? Find the answer in the table heading and notes, then check whether the total beneath the percentage uses that same unit. Imagine a record containing repeated entries and ask how the stated counting rule would handle it. Avoid performing a conversion until the required relationship between units is documented. Your finished annotation should let another reader identify exactly what was counted, including how repetition enters the calculation.
Questions to investigate
- What would one counted item represent under the table's stated definition?
- How would repeated entries from the same record enter the calculation?
- Does the total use the same unit as the items being counted?
Sources for this file
- EGRIFTA WRNLM · Checked
- Falutz trialPubMed · Checked
MED CONSUMER WATCH · RESEARCH
Read the evidence behind the question.
Browse reference files or follow a study analysis from its question to its limitations.